£277.64
CHROMagar
CHROMagar™ MRSA 5000mL pack
MRSA - Leading causes of nosocomial infections, especially in intensive care units, the MRSA sources are either endogenous (the patient) or through cross contamination (environmental or by person to person contact). The major issue with this pathogen is its resistance to a large panel of antibiotics, among them beta-lactam antibiotics, limiting the therapeutic options for clinicians.
In the UK, the estimation of the additional cost of discharging every hospital patient who acquires MRSA is £9,000.
CHROMagar™ MRSA is a selective and differential chromogenic medium for the qualitative direct detection of colonization by methicillin resistant Staphylococcus aureus (MRSA) to aid in the prevention and control of MRSA in healthcare settings. The test is performed on anterior nares or perineal swab specimens from patients and healthcare workers to screen for MRSA colonization. Results can be interpreted after 18-24 hours of aerobic incubation at 35-37 °C.
CHROMagar™ MRSA can also be used in conjunction with other laboratory tests and clinical data available to aid in the identification and in the diagnosis of MRSA infections in skin, soft tissue, wounds and positive blood cultures. Concomitant cultures are necessary to recover organisms for further microbiological susceptibility testing or epidemiological typing.
Introduced in 2002, CHROMagar™ MRSA, was the first chromogenic medium for MRSA detection. It lead to such significant reductions in both, the response time and laboratory workload, that it allowed an absolutely necessary wide-scale patient screening.
CHROMagar™ MRSA allows an accurate detection of MRSA with a higher level of sensitivity than oxacillin containing media.
CHROMagar
CHROMagar™ MRSA 5000mL pack
MRSA - Leading causes of nosocomial infections, especially in intensive care units, the MRSA sources are either endogenous (the patient) or through cross contamination (environmental or by person to person contact). The major issue with this pathogen is its resistance to a large panel of antibiotics, among them beta-lactam antibiotics, limiting the therapeutic options for clinicians.
In the UK, the estimation of the additional cost of discharging every hospital patient who acquires MRSA is £9,000.
CHROMagar™ MRSA is a selective and differential chromogenic medium for the qualitative direct detection of colonization by methicillin resistant Staphylococcus aureus (MRSA) to aid in the prevention and control of MRSA in healthcare settings. The test is performed on anterior nares or perineal swab specimens from patients and healthcare workers to screen for MRSA colonization. Results can be interpreted after 18-24 hours of aerobic incubation at 35-37 °C.
CHROMagar™ MRSA can also be used in conjunction with other laboratory tests and clinical data available to aid in the identification and in the diagnosis of MRSA infections in skin, soft tissue, wounds and positive blood cultures. Concomitant cultures are necessary to recover organisms for further microbiological susceptibility testing or epidemiological typing.
Introduced in 2002, CHROMagar™ MRSA, was the first chromogenic medium for MRSA detection. It lead to such significant reductions in both, the response time and laboratory workload, that it allowed an absolutely necessary wide-scale patient screening.
CHROMagar™ MRSA allows an accurate detection of MRSA with a higher level of sensitivity than oxacillin containing media.
